Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Brilliant Blue G Selectively Blocks ATP-Gated Rat P2X7 Receptors

Lin-Hua Jiang, Amanda B. Mackenzie, R. Alan North and Annmarie Surprenant
Molecular Pharmacology July 2000, 58 (1) 82-88; DOI: https://doi.org/10.1124/mol.58.1.82
Lin-Hua Jiang
Institute of Molecular Physiology, University of Sheffield, Sheffield, England
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda B. Mackenzie
Institute of Molecular Physiology, University of Sheffield, Sheffield, England
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Alan North
Institute of Molecular Physiology, University of Sheffield, Sheffield, England
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annmarie Surprenant
Institute of Molecular Physiology, University of Sheffield, Sheffield, England
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

There are few antagonists selective for subtypes of the several P2X receptors, but these are needed to identify the receptors expressed on native cells and tissues. In particular, P2X4 and P2X7 receptor subunits are colocalized on immune, epithelial, and exocrine gland cells, but both are relatively insensitive to suramin and pyridoxal-5-phosphate-6-azo-2′,4′-disulfonic acid derivative. In this article, we show that Coomassie Brilliant Blue G selectively inhibits P2X7 receptors with nanomolar affinity. We measured currents in response to P2X receptor activation in HEK293 cells heterologously expressing human or rat P2X1, P2X2, P2X3, P2X2/3, P2X4, P2X1/5, and P2X7 receptors. Brilliant Blue G produced a noncompetitive inhibition of rat and human P2X7 receptors with IC50 values of 10 and 200 nM, respectively. IC50 values for inhibition of the other receptors ranged from 2 to >30 μM; the rat and human P2X4 receptors showed IC50 values of >10 and 3.2 μM. Coomassie Blue G also blocked YO-PRO1 uptake and membrane blebbing, which are uniquely associated with activation of P2X7 receptors. Thus, Brilliant Blue G is at least 1000-fold more potent at rat P2X7 receptors than at rat P2X4 receptors.

Footnotes

    • Received January 24, 2000.
    • Accepted March 7, 2000.
  • Prof. Annmarie Surprenan, Institute of Molecular Physiology, Department Biomedical Science, Alfred Denny Bldg., Western Bank, University of Sheffield, Sheffield S10 2TN England. E-mail:a.surprenant{at}sheffield.ac.uk

  • This work was supported by The Wellcome Trust (A.S.) and AstraZeneca (R.A.N.).

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 58 (1)
Molecular Pharmacology
Vol. 58, Issue 1
1 Jul 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Brilliant Blue G Selectively Blocks ATP-Gated Rat P2X7 Receptors
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Brilliant Blue G Selectively Blocks ATP-Gated Rat P2X7 Receptors

Lin-Hua Jiang, Amanda B. Mackenzie, R. Alan North and Annmarie Surprenant
Molecular Pharmacology July 1, 2000, 58 (1) 82-88; DOI: https://doi.org/10.1124/mol.58.1.82

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Brilliant Blue G Selectively Blocks ATP-Gated Rat P2X7 Receptors

Lin-Hua Jiang, Amanda B. Mackenzie, R. Alan North and Annmarie Surprenant
Molecular Pharmacology July 1, 2000, 58 (1) 82-88; DOI: https://doi.org/10.1124/mol.58.1.82
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Therapeutic Effects of FGF23 Antagonists in Hyp Mice
  • TRPV3 and TRPV4 Channels Coassemble into Heterotetramers
  • Secretin Amino-Terminal Structure-Activity Relationships and Complementary Mutagenesis at the Site of Docking to the Secretin Receptor
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics